Prospection: Deep Insights into Understanding Treatment Efficacy
Technology advancements in the healthcare sector have profoundly improved patient care and treatment methodologies. However, the increasing sophistication brings massive datasets that must be parsed before they are valuable for healthcare professionals. Add this to…
How Global Patient-centric Intelligence Advances Rare Disease Insights
Patient-centric intelligence (PCI) is becoming increasingly important for improving outcomes for rare diseases, with over 300 million people living with them around the world. Treatment for these diseases can be expensive, time consuming and complex. From diagnosis to treatment, people living with rare diseases face common challenges, but by using real-world data from multiple countries, we can better understand treatment patterns and mobilize the real-world evidence needed to influence care pathways and bolster research. Increasing awareness and advocacy for rare disease research can help bring better outcomes for those affected.
Accelerating Effectiveness of Clinical Trials with Patient-centric Intelligence
Patient-centric intelligence can be utilised in early phases of pharma product development lifecycle for identification of unmet medical needs and opportunities and to improve the success rate of clinical trials, leading to faster drug development, successful market entry and treatments reaching patients sooner.
Total Economic Impact of Prospection
Partnering with Prospection empowers patient-level insights to drive business outcomes and promote precision medicine. What business benefit and costs savings does Prospection offer our clients.
Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia
This study aimed to examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.
Prospection Earns ISO/IEC 27001 Certification!
Prospection is now officially accredited by the internationally recognised ISO standards. The ISO/IEC 27001:2013 refers to a framework of evaluation that addresses an organisation’s information security management system (ISMS). The certification demonstrates our commitment to…
Prospection is a Gold Sponsor
Drive trust in the robustness of RWD and RWE from within your organisation. Join us at Reuter’s European pharma event 11-13 October.
Japan healthcare data access agreement
Prospection announces a unique data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. (MDV).
The Democratisation of Real-World Evidence
Real-world evidence is playing an increasingly important role in healthcare delivery.
RWD providing answers to real world questions
Real world data provides patient and disease insights. Prospection Co-founders, Eric Chung, CEO and Dr Peter Cronin, Head of Data & Partnerships, joined Techwire Asia’s, ‘Tech Means Business‘ podcast with Joe Green. Real world data…
Accelerate clinical trials with real world evidence. Prospection Partners with Novotech Health Holdings
Media Release Prospection and Novotech Partner Sydney, 25 January 2022 – Global healthcare data technology company, Prospection, and leading Asia-Pacific biotech specialist CRO, Novotech Health Holdings, announce an strategic partnership to combine the power of…
Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions
Gout is the most common form of inflammatory arthritis in men. Despite the availability of effective urate-lowering therapies (ULT), the management of gout is suboptimal due to poor persistence with ULT. This study examined national prescribing patterns of ULT to determine persistence with allopurinol in Australia.
